David Y. Bouffard

1.2k total citations
17 papers, 743 citations indexed

About

David Y. Bouffard is a scholar working on Molecular Biology, Infectious Diseases and Oncology. According to data from OpenAlex, David Y. Bouffard has authored 17 papers receiving a total of 743 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Infectious Diseases and 3 papers in Oncology. Recurrent topics in David Y. Bouffard's work include HIV/AIDS drug development and treatment (7 papers), Biochemical and Molecular Research (6 papers) and Acute Lymphoblastic Leukemia research (3 papers). David Y. Bouffard is often cited by papers focused on HIV/AIDS drug development and treatment (7 papers), Biochemical and Molecular Research (6 papers) and Acute Lymphoblastic Leukemia research (3 papers). David Y. Bouffard collaborates with scholars based in Canada, United States and France. David Y. Bouffard's co-authors include Richard L. Momparler, Louise F. Momparler, Joseph Ayoub, Henriette Gourdeau, Kevin J. Scanlon, Sanjeeva Reddy, Lisa D. Curcio, Shailaja Kasibhatla, Karen Meerovitch and Ling Qiu and has published in prestigious journals such as International Journal of Cancer, Pharmacology & Therapeutics and Biochemical Pharmacology.

In The Last Decade

David Y. Bouffard

17 papers receiving 697 citations

Peers

Countries citing papers authored by David Y. Bouffard

Since Specialization

Citations

This map shows the geographic impact of David Y. Bouffard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Y. Bouffard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Y. Bouffard more than expected).

Fields of papers citing papers by David Y. Bouffard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Y. Bouffard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Y. Bouffard. The network helps show where David Y. Bouffard may publish in the future.

Co-authorship network of co-authors of David Y. Bouffard

This figure shows the co-authorship network connecting the top 25 collaborators of David Y. Bouffard. A scholar is included among the top collaborators of David Y. Bouffard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Y. Bouffard. David Y. Bouffard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer 2007 ·BMC Cancer ·Vijaya L. Damaraju, David Y. Bouffard, Clarence Wong, Marilyn L. Clarke, John R. Mackey, Lorraine Leblond, Carol E. Cass, (unknown), Henriette Gourdeau	25
2	Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity 2004 ·Molecular Cancer Therapeutics ·Shailaja Kasibhatla, Henriette Gourdeau, Karen Meerovitch, John Drewe, Sanjeeva Reddy, Ling Qiu, Hong Zhang, (unknown), David Y. Bouffard, Quan Yang, John Herich, Serge Lamothe, Sui Xiong Cai, Ben Tseng	175
3	Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells 2003 ·Cancer Chemotherapy and Pharmacology ·David Y. Bouffard, Jacques Jolivet, Lorraine Leblond, Bettina A. Hamelin, (unknown), (unknown), (unknown), Henriette Gourdeau	10
4	Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts 2002 ·Cancer Chemotherapy and Pharmacology ·Henriette Gourdeau, Philippe Genne, Salam Kadhim, (unknown), Olivier Duchamp, (unknown), (unknown), David Y. Bouffard, Giorgio Attardo	12
5	BCH-1868 [(-)-2-R-dihydroxyphosphinoyl-5-(S)-(guanin-9'-yl-methyl) tetrahydrofuran]: a cyclic nucleoside phosphonate with antitumor activity. 2002 ·PubMed ·Lorraine Leblond, Giorgio Attardo, Bettina A. Hamelin, David Y. Bouffard, Nghe Nguyen‐Ba, Henriette Gourdeau	11
6	Pilot phase l-ll study on 5-aza-2??-deoxycytidine (Decitabine) in patients with metastatic lung cancer 1997 ·Anti-Cancer Drugs ·Richard L. Momparler, David Y. Bouffard, Louise F. Momparler, (unknown), (unknown), Joseph Ayoub	178
7	Ribozyme‐Mediated Cancer Gene Therapy 1997 ·International Journal of Urology ·Akira Irie, David Y. Bouffard, Kevin J. Scanlon	7
8	Oligonucleotides as modulators of cancer gene expression 1997 ·Pharmacology & Therapeutics ·Lisa D. Curcio, David Y. Bouffard, Kevin J. Scanlon	28
9	Anti-oncogene Ribozymes for Cancer Gene Therapy 1997 ·Advances in pharmacology ·Akira Irie, Hiroshi Kijima, (unknown), David Y. Bouffard, Toshiya Suzuki, Lisa D. Curcio, (unknown), (unknown), Kevin J. Scanlon	14
10	Oligonucleotide modulation of multidrug resistance 1996 ·European Journal of Cancer ·David Y. Bouffard, Toshika Ohkawa, Hiroaki Kijima, Akira Irie, T. Suzuki, Lisa D. Curcio, (unknown), (unknown), Kevin J. Scanlon	17
11	Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside 1995 ·Leukemia Research ·David Y. Bouffard, Richard L. Momparler	41
12	Enhancement of the antileukemic activity of 5-aza-2′-deoxycytidine by cyclopentenyl cytosine in HL-60 leukemic cells 1994 ·Anti-Cancer Drugs ·David Y. Bouffard, Louise F. Momparler, Richard L. Momparler	12
13	Kinetic studies on 2',2'-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase 1993 ·Biochemical Pharmacology ·David Y. Bouffard, (unknown), (unknown)	158
14	Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells 1991 ·Anti-Cancer Drugs ·David Y. Bouffard, Louise F. Momparler, Richard L. Momparler	34
15	Enhancement of anti‐neoplastic activity of cytosine arabinoside against human HL‐60 myeloid leukemic cells by 3‐deazauridine 1991 ·International Journal of Cancer ·Richard L. Momparler, David Y. Bouffard, Louise F. Momparler, Jeanine Marquet, J Zittoun, (unknown), R Zittoun	10
16	Cellular pharmacology of 1-?-d-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells 1990 ·Cancer Chemotherapy and Pharmacology ·Richard L. Momparler, (unknown), David Y. Bouffard, Louise F. Momparler	9
17	Comparison of antineoplastic activity of cytosine arafolnoside and 2',2'-difluorodeoxycytidine on human myeloid, T-cell and B-ceil leukemic cells 1990 ·European Journal of Pharmacology ·David Y. Bouffard, Louise F. Momparler, Richard L. Momparler	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact